{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:18:19Z","timestamp":1765369099250},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.ejim.2016.08.036","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T15:15:22Z","timestamp":1474038922000},"page":"13-19","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Anemia management in cancer patients with chronic kidney disease"],"prefix":"10.1016","volume":"36","author":[{"given":"Andras T.","family":"Deak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Troppan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander R.","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2016.08.036_bb0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrneph.2015.82","article-title":"Anaemia in kidney disease: harnessing hypoxia responses for therapy","volume":"11","author":"Koury","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"Suppl. 7A","key":"10.1016\/j.ejim.2016.08.036_bb0010","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1016\/j.amjmed.2003.12.008","article-title":"Prevalence and outcomes of anemia in cancer: a systematic review of the literature","volume":"116","author":"Knight","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2016.08.036_bb0015","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/ajh.23628","article-title":"Diagnosis and treatment of cancer-related anemia","volume":"89","author":"Gilreath","year":"2014","journal-title":"Am J Hematol"},{"issue":"Suppl. 1","key":"10.1016\/j.ejim.2016.08.036_bb0020","first-page":"S2","article-title":"The impact and management of anaemia in haematological malignancies","volume":"17","author":"Coiffier","year":"2000","journal-title":"Med Oncol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0025","first-page":"2","article-title":"Anemia in cancer patients","volume":"25","author":"Ludwig","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0030","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/blood.V80.7.1639.1639","article-title":"Progress in understanding the pathogenesis of the anemia of chronic disease","volume":"80","author":"Means","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2016.08.036_bb0035","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3109\/10428194.2013.802314","article-title":"Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin","volume":"55","author":"Tisi","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejim.2016.08.036_bb0040","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2141.1977.tb00628.x","article-title":"The anaemia of chronic disorders: studies of iron reutilization in the anaemia of experimental malignancy and chronic inflammation","volume":"35","author":"Zarrabi","year":"1977","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0045","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejim.2016.08.036_bb0050","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2016.08.036_bb0055","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1097\/01.ASN.0000092138.65211.71","article-title":"Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study","volume":"14","author":"Jurkovitz","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0735-1097(02)01938-1","article-title":"Anemia as a risk factor for cardiovascular disease in the atherosclerosis risk in communities (ARIC) study","volume":"40","author":"Sarnak","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0065","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1046\/j.1523-1755.2003.00109.x","article-title":"Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC study","volume":"64","author":"Abramson","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2016.08.036_bb0070","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","article-title":"Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review","volume":"91","author":"Caro","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ejim.2016.08.036_bb0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ndt\/gfg458","article-title":"Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the dialysis outcomes and practice patterns study (DOPPS)","volume":"19","author":"Locatelli","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2016.08.036_bb0080","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2016.08.036_bb0085","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.299.8.914","article-title":"Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia","volume":"299","author":"Bennett","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2016.08.036_bb0090","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2016.08.036_bb0095","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(03)01163-X","article-title":"Breast cancer trial with erythropoietin terminated unexpectedly","volume":"4","author":"Leyland-Jones","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0100","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2006.07.1514","article-title":"Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia","volume":"25","author":"Wright","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0105","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2016.08.036_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1681\/ASN.2010111133","article-title":"Against TREATing all patients alike: lessons from an FDA advisory committee meeting","volume":"22","author":"Winkelmayer","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0115","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/ki.2012.270","article-title":"Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s)","volume":"82","author":"Drueke","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2016.08.036_bb0120","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.ajkd.2014.05.013","article-title":"Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to reduce cardiovascular events with Aranesp therapy (TREAT) using a large US health plan database","volume":"64","author":"Thamer","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejim.2016.08.036_bb0125","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.2215\/CJN.04970512","article-title":"Critical and honest conversations: the evidence behind the \u201cchoosing wisely\u201d campaign recommendations by the American Society of Nephrology","volume":"7","author":"Williams","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"author":"FDA Drug Safety Communication","key":"10.1016\/j.ejim.2016.08.036_bb0130"},{"key":"10.1016\/j.ejim.2016.08.036_bb0135","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2016.08.036_bb0140","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","article-title":"The European cancer anaemia survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients","volume":"40","author":"Ludwig","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejim.2016.08.036_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107297","article-title":"Pre-treatment anemia is a poor prognostic factor in soft tissue sarcoma patients","volume":"9","author":"Szkandera","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2016.08.036_bb0150","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/ejh.12529","article-title":"The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients","volume":"95","author":"Troppan","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0155","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/asheducation-2010.1.351","article-title":"Parenteral iron therapy in cancer-associated anemia","volume":"2010","author":"Henry","year":"2010","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ejim.2016.08.036_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002042.pub2","article-title":"Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion","author":"Carless","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2016.08.036_bb0165","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0170","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/jnci\/94.16.1211","article-title":"Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy","volume":"94","author":"Vansteenkiste","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejim.2016.08.036_bb0175","article-title":"Erythropoietin or darbepoetin for patients with cancer","volume":"12","author":"Tonia","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2016.08.036_bb0180","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bjc.6605498","article-title":"Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes","volume":"102","author":"Glaspy","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejim.2016.08.036_bb0185","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1200\/JCO.2008.19.1130","article-title":"Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia","volume":"27","author":"Ludwig","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2016.08.036_bb0190","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1634\/theoncologist.2009-S1-43","article-title":"Anemia management in oncology and hematology","volume":"14","author":"Spivak","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.ejim.2016.08.036_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer\u2014meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2016.08.036_bb0200","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/ki.2013.528","article-title":"Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer","volume":"86","author":"Hazzan","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2016.08.036_bb0205","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdq709","volume":"22","author":"Untch","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0210","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/cas.12105","article-title":"Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: individual patient data from Japanese randomized, placebo-controlled trials","volume":"104","author":"Ohashi","year":"2013","journal-title":"Cancer Sci"},{"issue":"Suppl. 5","key":"10.1016\/j.ejim.2016.08.036_bb0215","doi-asserted-by":"crossref","first-page":"v244","DOI":"10.1093\/annonc\/mdq202","article-title":"Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO clinical practice guidelines for use","volume":"21","author":"Schrijvers","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0220","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1200\/JCO.2010.29.2201","article-title":"American Society of Clinical Oncology\/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer","volume":"28","author":"Rizzo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0225","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/asheducation-2008.1.159","article-title":"The anemia of inflammation\/malignancy: mechanisms and management","author":"Adamson","year":"2008","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ejim.2016.08.036_bb0230","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/annonc\/mds112","article-title":"Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0235","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjh.12311","article-title":"Guideline for the laboratory diagnosis of functional iron deficiency","volume":"161","author":"Thomas","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0240","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.2010.30.3644","article-title":"Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia","volume":"29","author":"Steensma","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0245","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s12032-014-0302-3","article-title":"Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy","volume":"31","author":"Hedenus","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0250","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2004.08.119","article-title":"Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial","volume":"22","author":"Auerbach","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0255","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.leu.2404562","article-title":"Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study","volume":"21","author":"Hedenus","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2016.08.036_bb0260","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1634\/theoncologist.12-2-231","article-title":"Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy","volume":"12","author":"Henry","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ejim.2016.08.036_bb0265","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00432-011-1072-3","article-title":"Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials","volume":"138","author":"Petrelli","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0275","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00508-015-0842-3","article-title":"Iron metabolism and iron supplementation in cancer patients","volume":"127","author":"Ludwig","year":"2015","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.ejim.2016.08.036_bb0280","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000337820","article-title":"Maximizing the erythropoietin response: iron strategies","volume":"178","author":"Prabhu","year":"2012","journal-title":"Contrib Nephrol"},{"issue":"2","key":"10.1016\/j.ejim.2016.08.036_bb0285","first-page":"279","article-title":"Clinical practice guideline for anemia in chronic kidney disease","volume":"2012","author":"KDIGO","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ejim.2016.08.036_bb0290","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/ndt\/gfq613","article-title":"A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients","volume":"26","author":"Qunibi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2016.08.036_bb0295","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrneph.2010.139","article-title":"Iron supplementation to treat anemia in patients with chronic kidney disease","volume":"6","author":"Besarab","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0300","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1681\/ASN.2007050606","article-title":"Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin","volume":"19","author":"Kapoian","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0305","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2016.08.036_bb0310","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/ndt\/gfv293","article-title":"A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia","volume":"31","author":"Kalra","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2016.08.036_bb0315","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1517\/14656566.2015.1079622","article-title":"Novel iron-containing phosphate binders for treatment of hyperphosphatemia","volume":"16","author":"Schmid","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ejim.2016.08.036_bb0320","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/ckj\/sfu139","article-title":"Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?","volume":"8","author":"Negri","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ejim.2016.08.036_bb0325","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.ajkd.2015.09.031","article-title":"New options for iron supplementation in maintenance hemodialysis patients","volume":"67","author":"Vaziri","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejim.2016.08.036_bb0330","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ki.2015.203","article-title":"Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients","volume":"88","author":"Gupta","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2016.08.036_bb0335","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/ndt\/gfv277","article-title":"Ferric pyrophosphate citrate (Triferic) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients","volume":"30","author":"Fishbane","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2016.08.036_bb0340","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/ki.2015.163","article-title":"A randomized trial of intravenous and oral iron in chronic kidney disease","volume":"88","author":"Agarwal","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2016.08.036_bb0345","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.ajkd.2015.01.034","article-title":"Calciphylaxis: risk factors, diagnosis, and treatment","volume":"66","author":"Nigwekar","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejim.2016.08.036_bb0350","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11255-011-0028-5","article-title":"Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD","volume":"44","author":"Van Buren","year":"2012","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0355","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11883-013-0358-0","article-title":"Iron deficiency and cardiovascular disease: an updated review of the evidence","volume":"15","author":"Lapice","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.ejim.2016.08.036_bb0360","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jacc.2010.03.083","article-title":"Iron overload cardiomyopathy: better understanding of an increasing disorder","volume":"56","author":"Gujja","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 7","key":"10.1016\/j.ejim.2016.08.036_bb0365","first-page":"vii2","article-title":"Epidemiology of cardiovascular risk in patients with chronic kidney disease","volume":"18","author":"Locatelli","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2016.08.036_bb0370","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2004030203","article-title":"Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999","volume":"16","author":"Foley","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0375","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/ki.2014.114","article-title":"Association between hemoglobin variability, serum ferritin levels, and adverse events\/mortality in maintenance hemodialysis patients","volume":"86","author":"Kuragano","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2016.08.036_bb0380","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ki.2014.275","article-title":"Data from the dialysis outcomes and practice patterns study validate an association between high intravenous iron doses and mortality","volume":"87","author":"Bailie","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2016.08.036_bb0385","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.2215\/CJN.02600315","article-title":"Understanding the recent increase in ferritin levels in United States dialysis patients: potential impact of changes in intravenous iron and erythropoiesis-stimulating agent dosing","volume":"10","author":"Karaboyas","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0395","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(99)06154-1","article-title":"Cancer in patients on dialysis for end-stage renal disease: an international collaborative study","volume":"354","author":"Maisonneuve","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2016.08.036_bb0400","first-page":"253","article-title":"Chronic kidney disease and cancer: a troubling connection","volume":"23","author":"Stengel","year":"2010","journal-title":"J Nephrol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0405","article-title":"Association of dialysis with the risks of cancers","volume":"10","author":"Lin","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2016.08.036_bb0410","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/01.ASN.0000039608.81046.81","article-title":"Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand","volume":"14","author":"Stewart","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2016.08.036_bb0415","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.ajkd.2014.12.013","article-title":"Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009","volume":"65","author":"Butler","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejim.2016.08.036_bb0420","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2016.08.036_bb0425","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(00)02298-4","article-title":"Cancer risk in patients on dialysis and after renal transplantation","volume":"355","author":"Birkeland","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2016.08.036_bb0430","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/ndt\/gfu387","article-title":"Onco-nephrology: an appraisal of the cancer and chronic kidney disease links","volume":"30","author":"Izzedine","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2016.08.036_bb0435","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1097\/01.TP.0000083897.44391.E8","article-title":"Incidence of cancer after kidney transplant: results from the North Italy transplant program","volume":"76","author":"Pedotti","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.ejim.2016.08.036_bb0440","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study","volume":"110","author":"Launay-Vacher","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejim.2016.08.036_bb0445","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/sj.bjc.6605979","article-title":"Cancer and renal insufficiency results of the BIRMA study","volume":"103","author":"Janus","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejim.2016.08.036_bb0450","first-page":"82","article-title":"The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells from clinic to bench \u2014 a critical review","volume":"2010","author":"Szenajch","year":"1806","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ejim.2016.08.036_bb0455","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.leukres.2012.04.017","article-title":"Erythropoietin: the swinging pendulum","volume":"36","author":"Oster","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.ejim.2016.08.036_bb0460","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000440771","article-title":"Trends in anemia management in hemodialysis patients with cancer","volume":"42","author":"Butler","year":"2015","journal-title":"Am J Nephrol"},{"issue":"Suppl. 3","key":"10.1016\/j.ejim.2016.08.036_bb0465","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1634\/theoncologist.2011-S3-25","article-title":"Iron supplementation in nephrology and oncology: what do we have in common?","volume":"16","author":"Macdougall","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.ejim.2016.08.036_bb0470","first-page":"301","article-title":"Intravenous iron-dextran: therapeutic and experimental possibilities","volume":"100","author":"Ganzoni","year":"1970","journal-title":"Schweiz Med Wochenschr"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620516303016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620516303016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T02:35:59Z","timestamp":1601087759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620516303016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":92,"alternative-id":["S0953620516303016"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2016.08.036","relation":{},"ISSN":["0953-6205"],"issn-type":[{"type":"print","value":"0953-6205"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anemia management in cancer patients with chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2016.08.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}